Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)

Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5) Publisher Pubmed

Gharaylou Z^{1, 7} ; Tafakhori A² ; Agah E^{3, 4} ; Aghamollaii V⁵ ; Kebriaeezadeh A⁶ ; Hadjighassem M^{1, 7, 8}

Show Affiliations

1. Department of Neuroscience and Addiction Study, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran
2. Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
3. Studentsâ€™ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
4. NeuroImmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
5. Department of Neurology, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
6. Pharmaceutical Management and Economic Research Center, Tehran University of Medical Sciences, Tehran, Iran
7. Department of Neuroscience and Addiction Study, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran
8. Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: CNS Drugs Published:2019

Abstract

Style	Citing Format
MLA	Gharaylou Z, et al.. "Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)." CNS Drugs, vol. 33, no. 8, 2019, pp. 839-.
APA	Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M (2019). Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5). CNS Drugs, 33(8), 839-.
Chicago	Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M. "Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)." CNS Drugs 33, no. 8 (2019): 839-.
Harvard	Gharaylou Z et al. (2019) 'Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)', CNS Drugs, 33(8), pp. 839-.
Vancouver	Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M. Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5). CNS Drugs. 2019;33(8):839-.
BibTex	@article{ author = {Gharaylou Z and Tafakhori A and Agah E and Aghamollaii V and Kebriaeezadeh A and Hadjighassem M}, title = {Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)}, journal = {CNS Drugs}, volume = {33}, number = {8}, pages = {839-}, year = {2019} }
RIS	TY - JOUR AU - Gharaylou Z AU - Tafakhori A AU - Agah E AU - Aghamollaii V AU - Kebriaeezadeh A AU - Hadjighassem M TI - Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5) JO - CNS Drugs VL - 33 IS - 8 SP - 839 EP - PY - 2019 ER -

Style

Citing Format

MLA

Gharaylou Z, et al.. "Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)." CNS Drugs, vol. 33, no. 8, 2019, pp. 839-.

APA

Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M (2019). Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5). CNS Drugs, 33(8), 839-.

Chicago

Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M. "Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)." CNS Drugs 33, no. 8 (2019): 839-.

Harvard

Gharaylou Z et al. (2019) 'Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)', CNS Drugs, 33(8), pp. 839-.

Vancouver

Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M. Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5). CNS Drugs. 2019;33(8):839-.

BibTex

@article{ author = {Gharaylou Z and Tafakhori A and Agah E and Aghamollaii V and Kebriaeezadeh A and Hadjighassem M}, title = {Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)}, journal = {CNS Drugs}, volume = {33}, number = {8}, pages = {839-}, year = {2019} }

RIS

TY - JOUR
AU - Gharaylou Z
AU - Tafakhori A
AU - Agah E
AU - Aghamollaii V
AU - Kebriaeezadeh A
AU - Hadjighassem M
TI - Correction To: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an Nkcc1 Inhibitor, in Patients With Drug-Resistant Epilepsy (Cns Drugs, (2019), 33, 3, (283-291), 10.1007/S40263-019-00607-5)
JO - CNS Drugs
VL - 33
IS - 8
SP - 839
EP -
PY - 2019
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract